Akebia Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The company is advancing a differentiated pipeline in kidney disease, with praliciguat, AKB-097, and AKB-9090 progressing through key clinical milestones. Vafseo is driving revenue growth, supporting R&D investments, and multiple catalysts are expected in the next year.
-
The company is focused on making Vafseo the standard of care for dialysis-related anemia, supported by strong clinical and economic data, and is expanding its kidney disease pipeline with praliciguat and AKB-097. Post-TDAPA, pricing will align with ESA benchmarks, targeting a $1B market.
-
The company is advancing its kidney disease portfolio, with VAFSEO gaining traction in dialysis anemia and new dosing strategies reducing discontinuation rates. Key clinical readouts for VAFSEO and pipeline assets like praliciguat and AKB-097 are expected over the next 12–24 months.
Fiscal Year 2025
-
Net product revenues grew nearly 50% year-over-year to $236.2 million in 2025, driven by Vafseo's launch and Auryxia sales, while net loss narrowed significantly. Vafseo adoption is expanding, with improved adherence and broader access, and the pipeline is advancing with multiple clinical milestones ahead.
-
The company is expanding its kidney disease portfolio with new pipeline assets and a successful Vafseo launch, despite operational and pricing challenges. Clinical data supports Vafseo's benefits, and new acquisitions strengthen the rare disease pipeline.
-
Vafseo's launch in the dialysis market is progressing, with expanding access and operational improvements expected to drive growth into 2026. Clinical data supports its efficacy and safety, while new dosing strategies and ongoing studies aim to establish it as standard of care.
-
Vafseo's U.S. launch has expanded patient access significantly, with DaVita and U.S. Renal Care as key partners. Recent clinical data show reduced mortality and hospitalization, supporting broader adoption. Financially, the company is well-capitalized and advancing a robust pipeline.
-
Vafseo prescriptions outpaced recent dialysis launches, with Q3 revenue at $14.3M and total company revenue up 57% year-over-year. Operational challenges are being addressed, and prescribing access is set to expand to over 260,000 patients by year-end, supporting long-term growth.
-
Vafseo's strong Q2 launch and broad adoption in dialysis centers are driving significant revenue growth, with major expansion opportunities ahead as protocols are operationalized in large organizations. The upcoming VALOR trial targets a multi-billion dollar non-dialysis market, while a solid cash position supports ongoing pipeline development.
-
Vafseo's U.S. launch is progressing strongly, with rapid expansion in prescribing access and robust physician engagement. The company is advancing pivotal trials for both dialysis and non-dialysis CKD populations, supported by a solid financial position and a growing pipeline.
-
Vafseo's launch is progressing with strong revenue growth and expanding access in the dialysis market, supported by favorable reimbursement during the Tdap period. Clinical data highlight safety and convenience advantages, while a large non-dialysis market opportunity is being pursued with a new study planned. Auryxia continues to contribute financially as generic competition is delayed.
-
Q2 saw record revenues driven by Vafseo's strong launch and AURYXIA's resilience, with expanded patient access and positive net income. Vafseo's reach is set to grow significantly in Q4 as DaVita comes online, and label expansion efforts for non-dialysis CKD are advancing.
-
Vafseo's launch is progressing well, with strong early adoption among small and mid-sized dialysis organizations and a major LDO pilot set for Q3. The company is shifting focus from Auryxia to Vafseo, targeting both dialysis and non-dialysis markets, and advancing a promising early-stage pipeline.
-
Vafseo's launch saw rapid physician adoption and broad payer coverage, with strong growth expected as pilots with large dialysis organizations begin. The NDD market offers significant expansion potential, supported by robust clinical data and a differentiated product profile. Financially, the company is well-positioned with $113M in cash and guidance through profitability.
-
Vafseo's U.S. launch for dialysis-related anemia is progressing rapidly, with strong physician adoption and broad coverage among dialysis providers. Expansion into non-dialysis markets and ongoing clinical trials are expected to drive significant future growth.
-
Q1 revenues surged to $57.3M, driven by a strong Vafseo launch and increased Auryxia sales, resulting in $6.1M net income. Vafseo adoption is expanding, with large dialysis pilots set to double patient access later in 2025. Cash reserves stand at $113.4M.
-
Vafseo launched in the U.S. with broad dialysis provider access and strong early physician adoption. The company is targeting both dialysis and non-dialysis CKD markets, supported by robust clinical trials and a solid financial position to fund operations and pipeline development for at least two years.
Fiscal Year 2024
-
Vafseo's U.S. launch for dialysis-related anemia exceeded early expectations, with strong prescriber uptake and $10–$11 million in Q1 revenue. Full-year 2024 revenue declined due to Auryxia volume, but cash runway is secure for at least two years.
-
Vafseo is set for imminent launch in the dialysis market, with strong provider contracts and high physician interest, and plans for label expansion into the larger non-dialysis segment. The VOICE trial and ongoing FDA engagement are expected to drive future growth and standard of care adoption.
-
Vafseo is set for imminent U.S. launch, targeting anemia in dialysis patients with a novel oral therapy and robust clinical data. The company is expanding provider contracts, pursuing a large non-dialysis market, and advancing a pipeline of HIF-based therapies, supported by strong financials.
-
Vafseo is on track for U.S. launch in January 2025, with 60% dialysis patient coverage through contracts and strong prescriber interest. Q3 revenue declined year-over-year, but cash runway is secure and key reimbursement milestones have been achieved.
-
Auryxia and Vafseo anchor a focused kidney disease portfolio, with Vafseo launching in January and targeting a $1B dialysis market. Strategic contracting, robust clinical data, and a strong cash position support rapid adoption and future pipeline growth.
-
Two commercial kidney disease therapies are advancing: Auryxia remains a stable revenue source as it enters the dialysis bundle, while Vafseo, newly approved for anemia in dialysis patients, is set for launch with strong provider incentives and a robust market opportunity. Early-stage pipeline assets and a solid cash position support future growth.
-
Vafseo, an oral anemia therapy for dialysis patients, is set for U.S. launch in January, targeting a $1B market with strong physician interest and premium pricing during the initial TDAPA period. Expansion into non-dialysis CKD and additional label indications are planned, supported by robust clinical data.
-
Q2 2024 revenue was $43.6M, with AURYXIA as the main driver and Vafseo launch on track for January. Contracting covers 90% of patient lives, and cash runway is secure for at least two years. Vafseo is also expanding internationally.
-
Significant innovation is transforming kidney disease treatment, with Vafseo poised to become a new oral standard for anemia in dialysis patients. Launch preparations focus on contracting, reimbursement, and physician adoption, while expansion into non-dialysis and new indications could double market potential.
-
Vafseo's US launch is advancing with strong prescriber interest, a validated $15,500 annual price, and a new royalty-based agreement with CSL Vifor that streamlines operations and enhances direct contracting. Plans for label expansion to non-dialysis CKD patients are progressing, with FDA engagement expected in 2024.
-
Vafseo, a novel oral anemia therapy for dialysis patients, is set for US launch in January to leverage TDAPA reimbursement, with preparations underway in contracting and market education. Expansion into non-dialysis CKD and new pipeline assets offer future growth potential.